Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells

Détails

ID Serval
serval:BIB_91BBDC9BC54E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells
Périodique
Oncoimmunology
Auteur⸱e⸱s
Delaunay T., Violland M., Boisgerault N., Dutoit S., Vignard V., Munz C., Gannage M., Dreno B., Vaivode K., Pjanova D., Labarriere N., Wang Y., Chiocca E. A., Boeuf F. L., Bell J. C., Erbs P., Tangy F., Gregoire M., Fonteneau J. F.
ISSN
2162-4011 (Print)
ISSN-L
2162-4011
Statut éditorial
Publié
Date de publication
2018
Volume
7
Numéro
3
Pages
e1407897
Langue
anglais
Notes
Delaunay, Tiphaine
Violland, Mathilde
Boisgerault, Nicolas
Dutoit, Soizic
Vignard, Virginie
Munz, Christian
Gannage, Monique
Dreno, Brigitte
Vaivode, Kristine
Pjanova, Dace
Labarriere, Nathalie
Wang, Yaohe
Chiocca, E Antonio
Boeuf, Fabrice Le
Bell, John C
Erbs, Philippe
Tangy, Frederic
Gregoire, Marc
Fonteneau, Jean-Francois
eng
MR/M015696/1/Medical Research Council/United Kingdom
Research Support, Non-U.S. Gov't
Oncoimmunology. 2017 Dec 26;7(3):e1407897. doi: 10.1080/2162402X.2017.1407897. eCollection 2018.
Résumé
Oncolytic immunotherapy using oncolytic viruses (OV) has been shown to stimulate the antitumor immune response by inducing the release of tumor-associated antigens (TAA) and danger signals from the dying infected tumor cells. In this study, we sought to determine if the lysis of tumor cells induced by different OV: measles virus, vaccinia virus, vesicular stomatitis virus, herpes simplex type I virus, adenovirus or enterovirus, has consequences on the capacity of tumor cells to present TAA, such as NY-ESO-1. We show that the co-culture of NY-ESO-1(neg)/HLA-DP4(pos) melanoma cells with NY-ESO-1(pos)/HLA-DP4(neg) melanoma cells infected and killed by different OV induces an intercellular transfer of NY-ESO-1 that allows the recognition of NY-ESO-1(neg)/HLA-DP4(pos) tumor cells by an HLA-DP4/NY-ESO-1(157-170)-specific CD4+ cytotoxic T cell clone, NY67. We then confirmed this result in a second model with an HLA-DP4+ melanoma cell line that expresses a low amount of NY-ESO-1. Recognition of this cell line by the NY67 clone is largely increased in the presence of OV productive infection. Altogether, our results show for the first time another mechanism of stimulation of the anti-tumor immune response by OV, via the loading of tumor cells with TAA that sensitizes them for direct recognition by specific effector CD4+ T cells, supporting the use of OV for cancer immunotherapy.
Mots-clé
*CD4+ T Lymphocytes, *Melanoma, *Oncolytic Viruses, *Oncolytic immunotherapy, *Tumor-Associated Antigens
Pubmed
Création de la notice
10/03/2022 10:43
Dernière modification de la notice
11/03/2022 6:33
Données d'usage